GO
Loading...

Enter multiple symbols separated by commas

Gilead Sciences Inc

More

  • LOS ANGELES, April 30- Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates. Excluding one-time items, Gilead earned $2.94 per share in the first quarter, outpacing the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S.

  • FOSTER CITY, Calif.— Gilead Sciences raked in $3.6 billion from sales of its newest hepatitis C pill, lifting the drugmaker's results past Wall Street expectations. Gilead Sciences Inc. said Thursday that its net income nearly doubled, and excluding one-time charges it reported a profit of $2.94 per share. Analysts expected net income of $2.31 per share on $6.76...

  • Trades to go as April winds down Thursday, 30 Apr 2015 | 2:12 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • Street picks: 10 stocks ready to pop Thursday, 30 Apr 2015 | 7:00 AM ET

    More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • Final Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 6:14 PM ET

    Amgen Inc. fell $1.51 or. 9 percent, to $160.98. Biogen Idec rose $9.10 or 2.4 percent, to $383.78. Celgene Corp. fell$. 32 or. 3 percent, to $113.20.

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • Midday Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 2:53 PM ET

    Amgen Inc. fell $1.39 or. 9 percent, to $161.10. Biogen Idec rose $8.25 or 2.2 percent, to $382.93. Celgene Corp. fell$. 69 or. 6 percent, to $112.83.

  • Early Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 10:45 AM ET

    Amgen Inc. rose$. 60 or. 4 percent, to $163.09. Biogen Idec rose $9.40 or 2.5 percent, to $384.08. Celgene Corp. rose$. 30 or. 3 percent, to $113.82.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Final Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 6:04 PM ET

    Amgen Inc. rose$. 11 or. 1 percent, to $162.49. Biogen Idec fell $14.59 or 3.7 percent, to $374.68. Celgene Corp. fell $1.20 or 1.0 percent, to $113.52.

  • Midday Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 1:50 PM ET

    Amgen Inc. rose $2.04 or 1.3 percent, to $164.42. Biogen Idec fell $8.05 or 2.1 percent, to $381.22. Celgene Corp. fell$. 81 or. 7 percent, to $113.91.

  • Early Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 10:39 AM ET

    Amgen Inc. fell$. 23 or. 1 percent, to $162.15. Biogen Idec fell $8.74 or 2.2 percent, to $380.53. Celgene Corp. fell $1.03 or. 9 percent, to $113.69.

  • Aetna has hiked its 2015 forecast beyond analyst expectations after booking a 17- percent jump in first-quarter earnings, as enrollment gains and moderate medical cost growth helped the nation's third-largest health insurer. Aetna said it now expects operating earnings this year to range between $7.20 and $7.40 per share. Company leaders told analysts in...

  • Merck hurdles Wall Street forecasts Tuesday, 28 Apr 2015 | 7:18 AM ET

    Drugmaker Merck& Co. easily beat Wall Street expectations, sending its shares up sharply, despite first-quarter profit plunging 44 percent. While Merck's prescription drug sales jumped 16 percent in the U.S. in the quarter, they were down sharply in the huge Europe and Japan markets and some other regions. The world's fifth-biggest drugmaker said its net...

  • US markets waver ahead of Fed meeting Monday, 27 Apr 2015 | 6:52 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Investors proved cautious ahead of the Federal Reserve's two-day policy meeting that ends on Wednesday.

  • Final Glance: Biotechnology companies Monday, 27 Apr 2015 | 6:06 PM ET

    Amgen Inc. fell $5.53 or 3.3 percent, to $162.38. Biogen Idec fell $12.44 or 3.1 percent, to $389.27. Celgene Corp. fell $4.00 or 3.4 percent, to $114.72.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower as investors weighed earnings and looked ahead to the beginning of the two-day Federal Reserve meeting on Tuesday.

  • Midday Glance: Biotechnology companies Monday, 27 Apr 2015 | 1:50 PM ET

    Amgen Inc. fell $5.07 or 3.0 percent, to $162.84. Biogen Idec fell $11.37 or 2.8 percent, to $390.34. Celgene Corp. fell $3.51 or 3.0 percent, to $115.20.

  • *Further gains in biotech, social media seen limited. *Investors view cyber security, cloud services as growth areas. NEW YORK, April 27- When the Nasdaq Composite last hit record highs during the dotcom era, fund manager Walter Price struggled with justifying paying 400 times a company's earnings for rapid growth.